CD274 and non-small cell lung carcinoma: A current phase II trial (CITYSCAPE-02, NCT03563716) is comparing the efficacy of PD-L1 inhibitors alone vs. a combination of TIGIT inhibitors with PD-L1 inhibitors in NSCLC patients.